105 related articles for article (PubMed ID: 28122374)
1. Impact of Vitamin D on the Clinical Outcome of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Report on a Series from a Single Institute.
Massironi S; Zilli A; Bernasconi S; Fanetti I; Cavalcoli F; Ciafardini C; Felicetta I; Conte D
Neuroendocrinology; 2017; 105(4):403-411. PubMed ID: 28122374
[TBL] [Abstract][Full Text] [Related]
2. Risk in dosing regimens for 25-OH vitamin D supplementation in chronic haemodialysis patients.
Albalate M; de la Piedra C; Ortiz A; Hernández Pérez J; Rubert M; Pérez Garcia R; Zazo P; Nieto L; de Sequera P; Egido J
Nephron Clin Pract; 2012; 121(3-4):c112-9. PubMed ID: 23221739
[TBL] [Abstract][Full Text] [Related]
3. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
4. Impact of Vitamin D Deficiency on Tumor Aggressiveness in Neuroendocrine Neoplasms.
Albertelli M; Petolicchio C; Brasili S; Pogna A; Boschetti M; Luciano G; Campana D; Gay S; Veresani A; Ferone D; Vera L
Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686803
[No Abstract] [Full Text] [Related]
5. Maternal vitamin D deficiency and vitamin D supplementation in healthy infants.
Pehlivan I; Hatun S; Aydoğan M; Babaoğlu K; Gökalp AS
Turk J Pediatr; 2003; 45(4):315-20. PubMed ID: 14768796
[TBL] [Abstract][Full Text] [Related]
6. Supplementation of Vitamin D Deficiency in Patients with Neuroendocrine Tumors Using Over-the-Counter Vitamin D3 Preparations.
Robbins HL; Symington M; Mosterman B; Goodby J; Davies L; Dimitriadis GK; Kaltsas G; Randeva HS; Weickert MO
Nutr Cancer; 2018 Jul; 70(5):748-754. PubMed ID: 29781720
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
8. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias.
Albers MB; Almquist M; Bergenfelz A; Nordenström E
Langenbecks Arch Surg; 2020 Mar; 405(2):137-143. PubMed ID: 32291468
[TBL] [Abstract][Full Text] [Related]
9. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm.
Cavalcoli F; Pusceddu S; Zilli A; Tamagno G; Femia D; Prinzi N; Travers J; Consonni D; Ciafardini C; Conte D; Massironi S
Scand J Gastroenterol; 2019 Sep; 54(9):1111-1117. PubMed ID: 31454281
[No Abstract] [Full Text] [Related]
11. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).
Kos-Kudła B; Blicharz-Dorniak J; Strzelczyk J; Bałdys-Waligórska A; Bednarczuk T; Bolanowski M; Boratyn-Nowicka A; Borowska M; Cichocki A; Ćwikła JB; Falconi M; Foltyn W; Handkiewicz-Junak D; Hubalewska-Dydejczyk A; Jarząb B; Junik R; Kajdaniuk D; Kamiński G; Kolasińska-Ćwikła A; Kowalska A; Król R; Królicki L; Krzakowski M; Kunikowska J; Kuśnierz K; Lampe P; Lange D; Lewczuk-Myślicka A; Lewiński A; Lipiński M; Londzin-Olesik M; Marek B; Nasierowska-Guttmejer A; Nawrocki S; Nowakowska-Duława E; Pilch-Kowalczyk J; Rosiek V; Ruchała M; Siemińska L; Sowa-Staszczak A; Starzyńska T; Steinhof-Radwańska K; Sworczak K; Syrenicz A; Szawłowski A; Szczepkowski M; Wachuła E; Zajęcki W; Zemczak A; Zgliczyński W; Zieniewicz K
Endokrynol Pol; 2017; 68(2):79-110. PubMed ID: 28597909
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.
Altieri B; Barrea L; Modica R; Bottiglieri F; de Cicco F; Muscogiuri G; Circelli L; Savarese G; Di Somma C; Savastano S; Colao A; Faggiano A
Endocrine; 2022 Feb; 75(2):623-634. PubMed ID: 34533768
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
Kamp K; Alwani RA; Korpershoek E; Franssen GJ; de Herder WW; Feelders RA
Eur J Endocrinol; 2016 Mar; 174(3):271-80. PubMed ID: 26643855
[TBL] [Abstract][Full Text] [Related]
16. How should incidental NEN of the pancreas and gastrointestinal tract be followed?
Ariotti R; Partelli S; Muffatti F; Andreasi V; Della Sala F; Falconi M
Rev Endocr Metab Disord; 2018 Jun; 19(2):139-144. PubMed ID: 29527619
[TBL] [Abstract][Full Text] [Related]
17. Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms.
Kikut J; Jasińska A; Pobłocki J; Brodowski J; Małgorzata S
Nutrients; 2020 Jun; 12(7):. PubMed ID: 32630081
[TBL] [Abstract][Full Text] [Related]
18. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.
Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A;
BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616
[TBL] [Abstract][Full Text] [Related]
19. The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic (GEP-NEN) System.
Gebauer N; Ziehm M; Gebauer J; Riecke A; Meyhöfer S; Kulemann B; von Bubnoff N; Steinestel K; Bauer A; Witte HM
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358883
[TBL] [Abstract][Full Text] [Related]
20. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
